The application discloses LTBP2 as a new biomarker for renal dysfunction； methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker； and kits and devices for measuring said biomarker and/or performing said methods. LTBP2 is also involved in glomerular filtration rate, dyspnea, acute heart failure, left ventricular hypertrophy, cardiac fibrosis, preeclampsia, pregnancy- associated proteinuria.
